Clarivate expects free cash flow to grow about 10% to 15% in 2027 from its exit level, helped by much lower one-time transactional costs, a full-year benefit of recent debt reduction and capital expenditure under 10% of revenue. The company completed a tender offer and debt repurchase totaling $533 million and expects leverage of about three and a half times for 2027.
CLVT · Clarivate PLC
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Clarivate expects free cash flow to grow 10% to 15% in 2027 from where it exits this year, helped by lower one-time transaction costs, lower cash interest and CapEx falling under 10% of revenue. A tender offer ended with a total $533 million debt repurchase, and the company expects about three and a half times leverage by the end of 2027.
Clarivate Science Holdings Corporation accepted $533,000,000 total aggregate principal amount of notes, with the 2028 Notes and 2029 Notes accepted at proration factors of approximately 67.9% and 45.5%, respectively.
Clarivate Plc announced pricing for tender offers of 3.875% Senior Secured Notes due 2028 and 4.875% Senior Notes due 2029, at $979.08 and $928.75 per $1,000 principal amount, with series caps of $415,000,000 and $118,000,000 after 2% increases.
Clarivate announced cash tender offers for certain debt securities, capped at $500,000,000 aggregate and scheduled to expire on November 10, 2026 unless extended.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Jul 29, 2026TL;DR. Clarivate reaffirmed its full-year 2026 outlook, expecting ~200 bps adjusted EBITDA margin expansion and ~$900M of debt paydown, while Q2 net loss widened to $268.6M due to a $221.7M non-cash goodwill impairment linked to the pending Life Sciences & Healthcare divestiture.
- + Full-year 2026 outlook reaffirmed with adjusted EBITDA margin guided to expand ~200 bps
- + Free cash flow guided at low end of $365M–$435M range with plan to retire ~$900M of debt using FCF and LS&H divestiture proceeds
- + H1 adjusted EBITDA margin expanded 90 bps to 41.6% on recurring growth and cost discipline
- + Total debt reduced by $218.4M in H1 via opportunistic repurchases at a discount to par
- + Organic ACV grew 1.5% with H1 subscription organic growth up 60 bps YoY to 1.2%
- − Q2 GAAP net loss widened to $268.6M ($0.42/share) on a $221.7M non-cash goodwill impairment tied to the LS&H divestiture
- − Q2 Adjusted EBITDA declined 5.5% to $247.2M, with H1 free cash flow down 23.5% to $122.9M
- − Full-year 2026 free cash flow guided to be flat YoY at low end of range due to ~$70M of one-time LS&H transaction costs
- − H1 operating cash flow declined 18.8% to $233.4M driven by lower EBITDA and higher working capital use
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| A&G Adjusted EBITDA non-GAAP | $136.5M | the three months ended June 30, 2026 filing | — |
| Adjusted diluted EPS non-GAAP | $0.38 | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA non-GAAP | $488.4M | first six months of 2026 | — |
|
|
|||
| Adjusted EBITDA margin non-GAAP | 41.6% | Six Months Ended June 30, 2026 | — |
| Adjusted net income non-GAAP | $242.4M | first six months of 2026 | — |
| Adjusted net income and Adjusted diluted EPS non-GAAP | 242.4M | Six Months Ended June 30, 2026 | — |
| Adjusted weighted average ordinary shares, diluted non-GAAP | 645M | Six Months Ended June 30, 2026 | — |
| Free cash flow non-GAAP | $122.9M | first six months of 2026 | — |
| H1 debt reduction | $218M | H1 2026 | — |
| IP Adjusted EBITDA non-GAAP | $86.4M | the three months ended June 30, 2026 filing | — |
| LS&H Adjusted EBITDA non-GAAP | $24.3M | the three months ended June 30, 2026 filing | — |
| Organic ACV and subs revenue growth | 2% | Q2 2026 | — |
| Organic ACV growth | 1.5% | second quarter of 2026 | — |
| Organic recurring revenues | 0.7% | first six months of 2026 | — |
| Organic revenues decrease | 0.4% | first six months of 2026 | — |
| Organic subscription growth | 0.7% | second quarter of 2026 | — |
| Organic transactional revenues decrease | 15.7% | second quarter of 2026 | — |
| Recurring Organic Growth | 0.7% | Q2 2026 | — |
| Recurring revenues | 0.5% | second quarter of 2026 | — |
| Subs Organic Growth | 1.2% | H1 2026 | — |
| total ACV | 3.1% | June 30, 2026 | — |
| Total Reportable Segments Adjusted EBITDA non-GAAP | $247.2M | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Information Technology Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CLVT
this stock
Clarivate PLC
|
$1.38B | -35.3% | +0.6% | — | 7.6% |
|
IBM
International Business Machines Corp
|
$214.50B | -22.8% | +7.6% | 19.3 | 1.9% |
|
ACN
Accenture plc
|
$152.20B | -15.2% | +6.5% | 16.8 | 3.2% |
|
INFY
Infosys Ltd
|
$47.43B | -33.9% | — | — | 2.1% |
|
CTSH
Cognizant Technology Solutions Corp
|
$25.91B | -30.2% | +7.0% | 10.6 | 5.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 18, 2026
- This year
- 29
Clarivate expects free cash flow to grow about 10% to 15% in 2027 from its exit level, helped by much lower one-time transactional costs, a full-year benefit of recent debt reduction and capital expenditure under 10% of revenue. The company completed a tender offer and debt repurchase totaling $533 million and expects leverage of about three and a half times for 2027.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CLVT | -6.9% | +22.7% | -14.6% | +30.9% | -35.3% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | -3.0% | +28.3% | -11.2% | +34.3% | -42.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.